Development of novel genomic blood biomarkers for neurodegenerative diseases

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 6, 2010, Pages 669-678

  Borovecki, Fran ^a   Habek, Mario ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Biomarker; genomics; microarray; neurodegenerative disease

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL PRACTICE; COHORT ANALYSIS; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DISEASE COURSE; GENE EXPRESSION; GENOMICS; HUMAN; HUNTINGTON CHOREA; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; PARKINSON DISEASE; STATISTICAL ANALYSIS; TRANSCRIPTOMICS; TREATMENT RESPONSE;

EID: 78649314577     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793237476     Document Type: Article

References (73)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69, 89-95.
2. Manolio, T. Novel risk markers and clinical practice. N. Engl. J. Med., 2003, 349, 1587-1589.
3. Scherzer, C.R. Chipping away at diagnostics for neurodegenerative diseases. Neurobiol. Dis., 2009, 35, 148-156.
4. Alonso, A.; Molenberghs, G.; Geys, H.; Buyse, M.; Vangeneugden, T. A unifying approach for surrogate marker validation based on Prentice's criteria. Stat. Med., 2006, 25, 205-221.
5. Lutterotti, A.; Berger, T.; Reindl, M. Biological markers for multiple sclerosis. Curr. Med. Chem., 2007, 14, 1956-1965.
6. Manolio, T.A.; Collins, F.S. The HapMap and genome-wide association studies in diagnosis and therapy. Annu. Rev. Med., 2009, 60, 443-456.
7. Ness, S.A. Microarray analysis: basic strategies for successful experiments. Mol. Biotechnol., 2007, 36, 205-219.
8. Phan, J.H.; Quo, C.F.; Wang, M.D. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics. Prog. Brain Res., 2006, 158, 83-108.
9. Ibarreta, D.; Urcelay, E.; Parrilla, R.; Ayuso, M.S. Distinct pH homeostatic features in lymphoblasts from Alzheimer's disease patients. Ann. Neurol., 1998, 44, 216-222.
10. Stieler, J.T.; Lederer, C.; Bruckner, M.K.; Wolf, H.; Holzer, M.; Gertz, H.J.; Arendt, T. Impairment of mitogenic activation of peripheral blood lymphocytes in Alzheimer's disease. NeuroReport, 2001, 12, 3969-3972.
11. Blandini, F.; Sinforiani, E.; Pacchetti, C.; Samuele, A.; Bazzini, E.; Zangaglia, R. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology, 2006, 66, 529-534.
12. Kerlero de Rosbo, N.; Milo, R.; Lees, M.B.; Burger, D.; Bernard, C.C.; Ben-Nun, A. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J. Clin. Invest., 1993, 92, 2602-2608.
13. Mahad, D.J.; Lawry, J.; Howell, S.J.; Woodroofe, M.N. Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse. Mult. Scler., 2003, 9, 189-198.
14. Vallittu, A.M.; Saraste, M.; Airas, L. CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta. Neurol. Res., 2007, 29, 763-766.
15. Achiron, A.; Gurevich, M.; Friedman, N.; Kaminski, N.; Mandel, M. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann. Neurol., 2004, 55, 410-417.
16. Borovecki, F.; Lovrecic, L.; Zhou, J.; Jeong, H.; Then, F.; Rosas, H.D.; Hersch, S.M.; Hogarth, P.; Bouzou, B.; Jensen, R.V.; Krainc, D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl. Acad. Sci. USA, 2005, 102, 11023-11028.
17. Scherzer, C.R.; Eklund, A.C.; Morse, L.J.; Liao, Z.; Locascio, J.J.; Fefer, D.; Schwarzschild, M.A.; Schlossmacher, M.G.; Hauser, M.A.; Vance, J.M.; Sudarsky, L.R.; Standaert, D.G.; Growdon, J.H.; Jensen, R.V.; Gullans, S.R. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl. Acad. Sci. USA, 2007, 104, 955-960.
18. Whitney, L.W.; Ludwin, S.K.; McFarland, H.F.; Biddison, W.E. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J. Neuroimmunol., 2001, 121, 40-48.
19. MAQC Consortium.; Shi, L.; Reid, L.H.; Jones, W.D.; Shippy, R.; Warrington, J.A.; Baker, S.C.; Collins, P.J.; de Longueville, F.; Kawasaki, E.S.; Lee, K.Y.; Luo, Y.; Sun, Y.A.; Willey, J.C.; Setterquist, R.A.; Fischer, G.M.; Tong, W.; Dragan, Y.P.; Dix, D.J.; Frueh, F.W.; Goodsaid, F.M.; Herman, D.; Jensen, R.V.; Johnson, C.D.; Lobenhofer, E.K.; Puri, R.K.; Schrf, U.; Thierry-Mieg, J.; Wang, C.; Wilson, M.; Wolber, P.K.; Zhang, L.; Amur, S.; Bao, W.; Barbacioru, C.C.; Lucas, A.B.; Bertholet, V.; Boysen, C.; Bromley, B.; Brown, D.; Brunner, A.; Canales, R.; Cao, X.M.; Cebula, T.A.; Chen, J.J.; Cheng, J.; Chu, T.M.; Chudin, E.; Corson, J.; Corton, J.C.; Croner, L.J.; Davies, C.; Davison, T.S.; Delenstarr, G.; Deng, X.; Dorris, D.; Eklund, A.C.; Fan, X.H.; Fang, H.; Fulmer-Smentek, S.; Fuscoe, J.C.; Gallagher, K.; Ge, W.; Guo, L.; Guo, X.; Hager, J.; Haje, P.K.; Han, J.; Han, T.; Harbottle, H.C.; Harris, S.C.; Hatchwell, E.; Hauser, C.A.; Hester, S.; Hong, H.; Hurban, P.; Jackson, S.A.; Ji, H.; Knight, C.R.; Kuo, W.P.; LeClerc, J.E.; Levy, S.; Li, Q.Z.; Liu, C.; Liu, Y.; Lombardi, M.J.; Ma, Y.; Magnuson, S.R.; Maqsodi, B.; McDaniel, T.; Mei, N.; Myklebost, O.; Ning, B.; Novoradovskaya, N.; Orr, M.S.; Osborn, T.W.; Papallo, A.; Patterson, T.A.; Perkins, R.G.; Peters, E.H.; Peterson, R.; Philips, K.L.; Pine, P.S.; Pusztai, L.; Qian, F.; Ren, H.; Rosen, M.; Rosenzweig, B.A.; Samaha, R.R.; Schena, M.; Schroth, G.P.; Shchegrova, S.; Smith, D.D.; Staedtler, F.; Su, Z.; Sun, H.; Szallasi, Z.; Tezak, Z.; Thierry-Mieg, D.; Thompson, K.L.; Tikhonova, I.; Turpaz, Y.; Vallanat, B.; Van, C.; Walker, S.J.; Wang, S.J.; Wang, Y.; Wolfinger, R.; Wong, A.; Wu, J.; Xiao, C.; Xie, Q.; Xu, J.; Yang, W.; Zhang, L.; Zhong, S.; Zong, Y.; Slikker, W., Jr. The MicroArray Quality Control (MAQC) project shows inter-and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol., 2006, 24, 1151-1161.
20. Baechler, E.C.; Batliwalla, F.M.; Karypis, G.; Gaffney, P.M.; Moser, K.; Ortmann, W.A.; Espe, K.J.; Balasubramanian, S.; Hughes, K.M.; Chan, J.P.; Begovich, A.; Chang, S.Y.; Gregersen, P.K.; Behrens, T.W. Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation. Genes Immun., 2004, 5, 347-353.
21. Comabella, M.; Martin, R. Genomics in multiple sclerosis-current state and future directions. J. Neuroimmunol., 2007, 187, 1-8.
22. McFarland, H.F.; Martin, R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol., 2007, 8, 913-919.
23. Weiner, H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann. Neurol., 2009, 65, 239-248.
24. Mahad, D.J.; Ransohoff, R.M. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin. Immunol., 2003, 15, 23-32.
25. Ramanathan, M.; Weinstock-Guttman, B.; Nguyen, L.T.; Badgett, D.; Miller, C.; Patrick, K.; Brownscheidle, C.; Jacobs, L. In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J. Neuroimmunol., 2001, 116, 213-219.
26. Bomprezzi, R.; Ringnér, M.; Kim, S.; Bittner, M.L.; Khan, J.; Chen, Y.; Elkahloun, A.; Yu, A.; Bielekova, B.; Meltzer, P.S.; Martin, R.; McFarland, H.F.; Trent, J.M. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet., 2003, 12, 2191-2199.
27. Wandinger, K.P.; Stürzebecher, C.S.; Bielekova, B.; Detore, G.; Rosenwald, A.; Staudt, L.M.; McFarland, H.F.; Martin, R. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol., 2001, 50, 349-357.
28. Koike, F.; Satoh, J.; Miyake, S.; Yamamoto, T.; Kawai, M.; Kikuchi, S.; Nomura, K.; Yokoyama, K.; Ota, K.; Kanda, T.; Fukazawa, T.; Yamamura, T. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J. Neuroimmunol., 2003, 139, 109-118.
29. Stürzebecher, S.; Wandinger, K.P.; Rosenwald, A.; Sathyamoorthy, M.; Tzou, A.; Mattar, P.; Frank, J.A.; Staudt, L.; Martin, R.; McFarland, H.F. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain, 2003, 126, 1419-1429.
30. Weinstock-Guttman, B.; Badgett, D.; Patrick, K.; Hartrich, L.; Santos, R.; Hall, D.; Baier, M.; Feichter, J.; Ramanathan, M. Genomic effects of IFN-beta in multiple sclerosis patients. J. Immunol., 2003, 171, 2694-2702.
31. Serrano-Fernández, P.; Möller, S.; Goertsches, R.; Fiedler, H.; Koczan, D.; Thiesen, H.J.; Zettl, U.K. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity, 2010, 43(2), 172-178.
32. Shoulson, I.; Fahn, S. Huntington disease: clinical care and evaluation. Neurology, 1979, 29, 1-3.
33. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov. Disord., 1996, 11, 136-142.
34. Lovrecic, L.; Kastrin, A.; Kobal, J.; Pirtosek, Z.; Krainc, D.; Peterlin, B. Gene expression changes in blood as a putative biomarker for Huntington's disease. Mov. Disord., 2009, 24, 2277-2281.
35. Harjes, P.; Wanker, E.E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci., 2003, 28, 425-433.
36. Sugars, K.L.; Rubinsztein, D.C. Transcriptional abnormalities in Huntington disease. Trends Genet., 2003, 19, 233-238.
37. Dunah, A.W.; Jeong, H.; Griffin, A.; Kim, Y.M.; Standaert, D.G.; Hersch, S.M.; Mouradian, M.M.; Young, A.B.; Tanese, N.; Krainc, D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science, 2002, 296, 2238-2243.
38. Cha, J.H. Transcriptional signatures in Huntington's disease. Prog. Neurobiol., 2007, 83, 228-248.
39. Luthi-Carter, R.; Strand, A.D.; Hanson, S.A.; Kooperberg, C.; Schilling, G.; La Spada, A.R.; Merry, D.E.; Young, A.B.; Ross, C.A.; Borchelt, D.R.; Olson, J.M. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet., 2002, 11, 1927-1937.
40. Ide, K.; Nukina, N.; Masuda, N.; Goto, J.; Kanazawa, I. Abnormal gene product identified in Huntington's disease lymphocytes and brain. Biochem. Biophys. Res. Commun., 1995, 209, 1119-1125.
41. Sawa, A.; Wiegand, G.W.; Cooper, J.; Margolis, R.L.; Sharp, A.H.; Lawler, J.F., Greenamyre, J.T.; Snyder, S.H.; Ross, C.A. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med., 1999, 5, 1194-1198.
42. Panov, A.; Obertone, T.; Bennett-Desmelik, J.; Greenamyre, J.T. Ca(2+)-dependent permeability transition and complex I activity in lymphoblast mitochondria from normal individuals and patients with Huntington's or Alzheimer's disease. Ann. NY Acad. Sci., 1999, 893, 365-368.
43. 2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol. Cell Biochem., 2005, 269, 143-152.
44. Saft, C.; Zange, J.; Andrich, J.; Muller, K.; Lindenberg, K.; Landwehrmeyer, B.; Vorgerd, M.; Kraus, P.H.; Przuntek, H.; Schöls, L. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov. Disord., 2005, 20, 674-679.
45. Runne, H.; Kuhn, A.; Wild, E.J.; Pratyaksha, W.; Kristiansen, M.; Isaacs, J.D.; Régulier, E.; Delorenzi, M.; Tabrizi, S.J.; Luthi-Carter, R. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc. Natl. Acad. Sci. USA, 2007, 104, 14424-14429.
46. rd ed. Informa Health Care; London, 2003, pp. 71-98.
47. Hughes, A.J.; Daniel, S.E.; Kilford, L.; Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry, 1992, 55, 181-184.
48. Fearnley, J.M.; Lees, A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 1991, 114, 2283-2301.
49. Sunada, Y.; Saito, F.; Matsumura, K.; Shimizu, T. Differential expression of the parkin gene in the human brain and peripheral leukocytes. Neurosci. Lett., 1998, 254, 180-182.
50. Nagai, Y.; Ueno, S.; Saeki, Y.; Soga, F.; Hirano, M.; Yanagihara, T. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology, 1996, 46, 791-795.
51. Barbanti, P.; Fabbrini, G.; Ricci, A.; Cerbo, R.; Bronzetti, E.; Caronti, B. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov. Disord., 1999, 14, 764-771.
52. Caronti, B.; Antonini, G.; Calderaro, C.; Ruggieri, S.; Palladini, G.; Pontieri, F.E.; Colosimo, C. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J. Neural Transm., 2001, 108, 803-807.
53. Yoshino, H.; Nakagawa-Hattori, Y.; Kondo, T.; Mizuno, Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect., 1992, 4, 27-34.
54. Schulz, J.B.; Beal, M.F. Mitochondrial dysfunction in movement disorders. Curr. Opin. Neurol., 1994, 7, 333-339.
55. Miller, D.W.; Hague, S.M.; Clarimon, J.; Baptista, M.; Gwinn-Hardy, K.; Cookson, M.R.; Singleton, A.B. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology, 2004, 62, 1835-1838.
56. Soreq, L.; Israel, Z.; Bergman, H.; Soreq, H. Advanced microarray analysis highlights modified neuro-immune signaling in nucleated blood cells from Parkinson's disease patients. J. Neuroimmunol., 2008, 201-202, 227-236.
57. Selkoe, D.J. The molecular pathology of Alzheimer's disease. Neuron, 1991, 6, 487-498.
58. Chertkow, H.; Bergman, H.; Schipper, H.M.; Gauthier, S.; Bouchard, R.; Fontaine, S.; Clarfield, A.M. Assessment of suspected dementia. Can. J. Neurol. Sci., 2001, 28, S28-S41.
59. Lyketsos, C.G.; Steinberg, M.; Tschantz, J.; Norton, M.; Steffens, D.; Breitner, J.C.S. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry, 2000, 157, 708-714.
60. Schlossmacher, M.; Ostaszewski, B.L.; Hecker, L.I.; Celi, A.; Haass, C.; Chin, D.; Lieberburg, I.; Furie, B.C.; Furie, B.; Selkoe, D.J. Detection of distinct isoform patterns of the beta-amyloid precursor protein in human platelets and lymphocytes. Neurobiol. Aging, 1992, 13, 421-434.
61. Citron, M.; Vigo-Pelfrey, C.; Teplow, D.B.; Miller, C.; Schenk, D.; Johnston, J.; Winblad, B.; Venizelos, N.; Lannfelt, L.; Selkoe, D.J. Excessive production of amyloid beta protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc. Natl. Acad. Sci. USA, 1994, 91, 11993-11997.
62. Palotás, A.; Kálmán, J.; Laskay, G.; Juhász, A.; Janka, Z.; Penke, B. Comparative studies on [Ca2+]i-level of fibroblasts from Alzheimer patients and control individuals. Neurochem. Res., 2001, 26, 817-820.
63. Zubenko, G.S.; Cohen, B.M.; Growdon, J.; Corkin, S. Cell membrane abnormality in Alzheimer's disease. Lancet, 1984, 2, 235.
64. Kálmán, J.; Dey, I.; Ilona, S.V.; Matkovics, B.; Brown, D.; Janka, Z.; Farkas, T.; Joó, F. Platelet membrane fluidity and plasma malondialdehyde levels in Alzheimer's demented patients with and without family history of dementia. Biol. Psychiatry, 1994, 35, 190-194.
65. Zubenko, G.S. Endoplasmic reticulum abnormality in Alzheimer's disease: selective alteration in platelet NADH cytochrome C reductase activity. J. Geriatr. Psychiatry Neurol., 1989, 2, 3-10.
66. Scherzer, C.R.; Offe, K.; Gearing, M.; Rees, H.D.; Fang, G.; Heilman, C.J.; Schaller, C.; Bujo, H.; Levey, A.I.; Lah, J.J. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch. Neurol., 2004, 61, 1200-1205.
67. Kálmán, J.; Kitajka, K.; Pákáski, M.; Zvara, A.; Juhász, A.; Vincze, G.; Janka, Z.; Puskás, L.G. Gene expression profile analysis of lymphocytes from Alzheimer's patients. Psychiatr. Genet., 2005, 15, 1-6.
68. Maes, O.C.; Xu, S.; Yu, B.; Chertkow, H.M.; Wang, E.; Schipper, H.M. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol. Aging, 2007, 28, 1795-1809.
69. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75, 843-854.
70. Ruvkun, G.; Wightman, B.; Ha, I. The 20 years it took to recognize the importance of tiny RNAs. Cell, 2004, 116, S93-S96.
71. Ambros, V. The functions of animal microRNAs. Nature, 2004, 431, 350-355.
72. Lim, L.P.; Lau, N.C.; Garrett-Engele, P.; Grimson, A.; Schelter, J.M.; Castle, J.; Bartel, D.P.; Linsley, P.S.; Johnson, J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 2005, 433, 769-773.
73. Schipper, H.M.; Maes, O.C.; Chertkow, H.M.; Wang, E. MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul. Syst. Biol. 2007, 1, 263-274.